Literature DB >> 6821429

Treatment of tinnitus with tocainide hydrochloride.

J R Emmett, J J Shea.   

Abstract

Intravenous (IV) injection of lidocaine was used in patients with tinnitus for combined treatment with oral anticonvulsants carbamazepine (Tegretol) and primidone (Mysoline). In most cases, the high complication rate with these drugs precluded their long-term use. Tocainide hydrochloride (HCl), a primary amine analog of lidocaine, can be taken orally and was evaluated for the use in the treatment of tinnitus. A double-blind study in which one group received 200 mg tocainide HCl four times a day and one group received a placebo revealed no significant differences in tinnitus relief between the two groups. A single-blind study in which 600 mg tocainide HCl four times a day was administered showed 80% to 98% tinnitus relief in five of the six patients who tolerated the drug. Tocainide HCl treatment of tinnitus is promising.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6821429

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

Review 1.  Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy.

Authors:  C H Norris
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

2.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

Review 3.  Ménière's disease. A practical approach to management.

Authors:  G B Brookes
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

Review 4.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

5.  The value of tocainide in the treatment of tinnitus. A double-blind controlled study.

Authors:  J H Hulshof; P Vermeij
Journal:  Arch Otorhinolaryngol       Date:  1985
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.